Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding
暂无分享,去创建一个
C. Cannon | E. Hagström | J. López-Sendón | G. Maurer | A. Siegbahn | L. Wallentin | R. Becker | H. Katus | P. Steg | S. James | R. Storey | D. Lindholm | A. Himmelmann
[1] C. Cannon,et al. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. , 2017, Clinical chemistry.
[2] L. Wallentin,et al. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. , 2017, Clinical chemistry.
[3] C. Held,et al. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. , 2017, Clinical chemistry.
[4] J. Spertus,et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. , 2016, JAMA.
[5] E. Hagström,et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. , 2016, European heart journal.
[6] Marc P. Bonaca,et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. , 2015, European heart journal.
[7] Baris Gencer,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .
[8] M. Valgimigli,et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. , 2015, The New England journal of medicine.
[9] Braunwald,et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.
[10] R. de Caterina,et al. Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial , 2014, Circulation.
[11] C. Held,et al. Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial , 2014, Circulation.
[12] L. Lind,et al. GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men , 2013, PloS one.
[13] R. Vasan,et al. Biomarkers of cardiovascular stress and incident chronic kidney disease. , 2013, Clinical chemistry.
[14] K. Unsicker,et al. The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. , 2013, Cytokine & growth factor reviews.
[15] L. Lind,et al. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. , 2013, Clinical chemistry.
[16] A. Zarbock,et al. GDF‐15 prevents platelet integrin activation and thrombus formation , 2013, Journal of thrombosis and haemostasis : JTH.
[17] U. Haberkorn,et al. Growth Differentiation Factor‐15 Deficiency Inhibits Atherosclerosis Progression by Regulating Interleukin‐6–Dependent Inflammatory Response to Vascular Injury , 2012, Journal of the American Heart Association.
[18] A. Khera,et al. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study. , 2012, Clinical chemistry.
[19] L. Lind,et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. , 2009, European heart journal.
[20] W. Ahmad. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. , 2009 .
[21] A. Skene,et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2009, American heart journal.
[22] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[23] A. Siegbahn,et al. Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non–ST-Elevation Acute Coronary Syndrome , 2007, Circulation.
[24] R. Califf,et al. Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome , 2007, Circulation.
[25] K. Unsicker,et al. Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions , 2004, Cell and Tissue Research.
[26] Salim Yusuf,et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.